| Attribute |
Value |
| 52 Week Change |
-0.8595559 |
| Address1 |
501 Canal Blvd |
| All Time High |
51.375 |
| All Time Low |
0.0637 |
| Ask |
0.086 |
| Ask Size |
11,000,000 |
| Audit Risk |
8 |
| Average Daily Volume10 Day |
6,343,866 |
| Average Volume |
9,179,055 |
| Average Volume10Days |
6,343,866 |
| Beta |
1.295 |
| Bid |
0.0821 |
| Bid Size |
2,000,000 |
| Board Risk |
3 |
| Book Value |
-0.046 |
| City |
Richmond |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
8 |
| Country |
United States |
| Currency |
USD |
| Current Price |
0.074 |
| Current Ratio |
0.698 |
| Date Short Interest |
1,776,211,200 |
| Day High |
0.13 |
| Day Low |
0.0637 |
| Ebitda |
-106,662,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-0.097 |
| Enterprise To Revenue |
0.301 |
| Enterprise Value |
10,397,284 |
| Exchange |
PNK |
| Exchange Timezone Name |
UTC |
| Fifty Day Average |
0.1537604 |
| Fifty Two Week High |
0.766 |
| Fifty Two Week Low |
0.0637 |
| Financial Currency |
USD |
| First Trade Date Epoch Utc |
955,027,800 |
| Float Shares |
370,038,655 |
| Forward Eps |
-0.1 |
| Forward P E |
-0.74 |
| Free Cashflow |
-48,575,248 |
| Full Time Employees |
142 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,780,531,200 |
| Gross Margins |
-2.27673 |
| Gross Profits |
-78,677,000 |
| Held Percent Insiders |
0.0176 |
| Held Percent Institutions |
0.25843 |
| Implied Shares Outstanding |
414,288,847 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. ALS and Frontotemporal Lobar Degeneration; Takeda Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California. |
| Long Name |
Sangamo Therapeutics, Inc. |
| Market Cap |
30,657,374 |
| Max Age |
86,400 |
| Message Board Id |
finmb_412674 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-123,330,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
30,657,374 |
| Number Of Analyst Opinions |
2 |
| Open |
0.13 |
| Operating Cashflow |
-90,341,000 |
| Operating Margins |
-22.15395 |
| Overall Risk |
4 |
| Payout Ratio |
0.0 |
| Phone |
510 970 6000 |
| Previous Close |
0.074 |
| Price Hint |
4 |
| Price To Sales Trailing12 Months |
0.8871538 |
| Profit Margins |
0.0 |
| Quick Ratio |
0.639 |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
2.0 |
| Regular Market Day High |
0.13 |
| Regular Market Day Low |
0.0637 |
| Regular Market Open |
0.13 |
| Regular Market Previous Close |
0.074 |
| Regular Market Volume |
28,502,598 |
| Return On Assets |
-0.94369006 |
| Revenue Growth |
-0.776 |
| Revenue Per Share |
0.107 |
| Sand P52 Week Change |
0.2011286 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
2 |
| Shares Outstanding |
414,288,847 |
| Shares Percent Shares Out |
0.1035 |
| Shares Short |
42,883,635 |
| Shares Short Previous Month Date |
1,773,360,000 |
| Shares Short Prior Month |
33,481,264 |
| Short Name |
Sangamo Therapeutics, Inc. |
| Short Percent Of Float |
0.1042 |
| Short Ratio |
5.55 |
| State |
CA |
| Symbol |
SGMO |
| Target High Price |
2.0 |
| Target Low Price |
1.0 |
| Target Mean Price |
1.5 |
| Target Median Price |
1.5 |
| Time Zone Full Name |
America/New_York |
| Time Zone Short Name |
EDT |
| Total Cash |
27,586,000 |
| Total Cash Per Share |
0.067 |
| Total Debt |
19,332,000 |
| Total Revenue |
34,557,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.38 |
| Trailing Peg Ratio |
None |
| Two Hundred Day Average |
0.3747101 |
| Underlying Symbol |
SGMO |
| Uuid |
204a90d5-6f3d-377d-ac4a-5d324a9a4123 |
| Volume |
28,502,598 |
| Website |
https://www.sangamo.com |
| Zip |
94,804 |